272309 Overview of risk assessment and public health assessment

Tuesday, October 30, 2012 : 4:30 PM - 4:50 PM

Yolanda Anita Sanchez, MS, MPA , Office of Solid Waste and Emergency Response, Office of Superfund Remediation and Technology and Innovation, U.S. Environmental Protection Agency, Washington, DC
This presentation will begin with the history of the risk assessment framework used by the US EPA, as well as other organizations and federal agencies. A brief overview of each “phase” in the risk assessment process will be given, with supplemental resources for the audience to further explore on their own time. This presentation will also discuss public health assessment, a type of assessment unique to the Agency for Toxic Substances and Disease Registry (ATSDR).

Both processes identify the pollutants involved, determine a relationship between the dose of the pollutant and a specific biological response, identify the pathways by which the pollutant can expose individuals, and estimate the potential for adverse health effects to occur from exposure to the pollutant. However, public health assessments are always site-specific evaluations; employ environmental and biologic data; survey community health concerns; identify health effects data; and develop site-specific exposure scenarios.

Learning Areas:
Environmental health sciences
Public health or related education
Public health or related laws, regulations, standards, or guidelines

Learning Objectives:
- Explain the difference between public health assessment and risk assessment - Describe the four steps of a risk assessment

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am the National Program Manager for the "Community Involvement University" for the US EPA Superfund program. I have a MS in environmental health. My scientific interests include risk communication training and tool development.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.